Immutep Limited - PRRUF stock

Click the button to add PRRUF to the list of your stock picks.

Pick this!

Recently Updated Wikis

• BMNM
  Bimini Capital Management Inc
• CHALF
  Chalice Brands Ltd
• RECAF
  Reconnaissance Energy Africa Ltd
• BVNKF
  Bavarian Nordic A/S
• FBDS
  Fuss Brands Corp
• ALYI
  Alternet Systems Inc
• AFGYF
  AFC Energy plc
• GLATF
  Global Atomic Corp
• JSDA
  Jones Soda Co
• ILIKF
  Ilika Plc

OTC Symbol: PRRUF | OTC Tier: Pink Current

Description

Immutep Limited, a biotechnology company headquartered in Sydney, Australia, specializes in pharmaceutical research and development, focusing on immunotherapeutic products for treating cancer and autoimmune diseases. Its lead product candidate, eftilagimod alpha (efti or IMP321), is currently in a Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. Additionally, the company is working on several other candidates, including TACTI-002, TACTI-003, INSIGHT-003, and INSIGHT-005, targeting different types of cancers in various clinical trial phases. Immutep Limited also offers IMP761, IMP701, and IMP731, which are designed for autoimmune diseases and T cell-related treatments. The company collaborates with various pharmaceutical firms, such as GlaxoSmithKline, Novartis, Merck & Co., Inc., and others. It was previously known as Prima BioMed Ltd before changing its name in November 2017, and it was incorporated in 1987.

History

Immutep Limited has its origin in the company Prima BioMed Ltd, which was founded in 1987. The company was initially focused on developing technology related to immune-based therapies for the treatment of cancer and autoimmune diseases. Over the years, Prima BioMed expanded its research and development efforts in the field of immunotherapy.

In November 2017, Prima BioMed underwent a name change and rebranded itself as Immutep Limited. The name change was part of the company's strategic evolution to emphasize its focus on immunotherapy and immune-based therapies.

Products

The company's lead product candidate, eftilagimod alpha (efti or IMP321), gained significant attention and progressed through clinical trials, showcasing its potential as a promising immunotherapy for cancer treatment. Other research and development initiatives are in process, with a particular emphasis on developing novel immunotherapeutic products for the treatment of cancer and autoimmune diseases.